Edesa Biotech, Inc. (EDSA) News
Filter EDSA News Items
EDSA News Results
|Loading, please wait...|
EDSA News Highlights
- For EDSA, its 30 day story count is now at 12.
- Over the past 19 days, the trend for EDSA's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- The most mentioned tickers in articles about EDSA are ARDS, ATIF and KULR.
Latest EDSA News From Around the Web
Below are the latest news stories about Edesa Biotech Inc that investors may wish to consider to help them evaluate EDSA as an investment opportunity.
As Edesa Biotech, Inc. (NASDAQ:EDSA) gains 11%, insiders who bought last year may be wishing they had bet higher
Edesa Biotech, Inc. ( NASDAQ:EDSA ) insiders who bought shares over the past year were rewarded handsomely last week...
Introduction Edesa Biotech (EDSA) is a Canadian clinical-stage biotech company. EDSA has two lead candidates, EB05 and EB01. Both are in later stage clinical studies. EB05 is a monoclonal antibody therapy for Acute Respiratory Distress Syndrome ((ARDS)). ARDS is a life-threatening form of respiratory failure, and the leading cause of...
Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock rallied over 100% yesterday. uCloudlink Group Inc. (NASDAQ: UCL) dropped 17.4% to close at $5.08 after gaining 14% on Monday. Movano Inc. (NASDAQ: MOVE) fell 16.4% to settle at $3.22. KULR Technology Group, Inc. (NYSE: KULR) declined 13.2% to settle at $2.37. ATIF Holdings Limited (NASDAQ: ATIF) fell 12.9% to settle at $3.4850. RBC Be
Good morning, trader!
Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride.
Thinking about buying stock in Edesa Biotech, AVEO Pharmaceuticals, Lucid Group, FuelCell Energy, or Nikola Corp?
NEW YORK , Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, AVEO, LCID, FCEL, and NKLA. Full story available on Benzinga.com
Edesa Biotech (EDSA.Q) announced positive results today from its Phase 2 portion of an ongoing Phase 2/3 clinical study. This study is intended to evaluate EB05, the Companys monoclonal antibody candidate, as a single-dose treatment for hospitalized COVID-19 patients. The strong effect in reducing death in the most critically ill hospitalized patients who have been  The post Edesa Biotech (EDSA.Q) Announces Positive Phase 2 Data for EB05, Shares Climb +30% appeared first on Equity.Guru .
FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients Edesa Biotech, Inc. (NASDAQ: EDSA) surged over 60% in premarket trading after the company announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study The post The Buzz Show: Edesa Biotech (NASDAQ: EDSA) Clinical Study for Covid-19 Treatment first appeared on Financial Buzz .
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care. An independent Data and Safety Monitoring Board concluded that "a clinically important efficacy signal" was detected and that the study "met its objective." The DSMB recommended continuation of the study into
Edsa Biotech Inc. (NASDAQ: EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in risk of dying when treated with EB05 over standard care. Edsa Biotech's stock is trading up 63% to $9.63 at the time of publication. See Also: Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know Edsa Biotech Daily Chart Analysis Shares saw a large